Cubicin and Hearing loss - a phase IV clinical study of FDA data

Summary:

Hearing loss is reported as a side effect among people who take Cubicin (daptomycin), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Oxycodone, and have Lymphoma.

The phase IV clinical study analyzes which people have Hearing loss when taking Cubicin. It is created by eHealthMe based on reports of 7,953 people who have side effects when taking Cubicin from the FDA, and is updated regularly.

What is Cubicin?

Cubicin has active ingredients of daptomycin. It is often used in infection. eHealthMe is studying from 7,991 Cubicin users. Check the latest studies of Cubicin.

What is Hearing loss?

Hearing loss is found to be associated with 1,355 drugs and 2,378 conditions by eHealthMe. Check the latest studies of Hearing loss.

On Jul, 17, 2026

7,953 people reported to have side effects when taking Cubicin.
Among them, 11 people (0.14%) have Hearing loss.

Among these 11 people:

How long have people been on Cubicin when they have Hearing loss? *

What is the gender of people who have Hearing loss when taking Cubicin? *

female: 70 %
male: 30 %

What is the age of people who have Hearing loss when taking Cubicin? *

What are other drugs people take besides Cubicin? *

What are other side effects people have besides Hearing loss? *

Weaning Failure: 1 person, 9.09%
Gastric Ulcer (stomach ulcer): 1 person, 9.09%
Agitation (state of anxiety or nervous excitement): 1 person, 9.09%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 9.09%
Back Pain: 1 person, 9.09%
Blood Pressure Diastolic Decreased: 1 person, 9.09%
Cardiac Failure Acute: 1 person, 9.09%
Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 1 person, 9.09%
Complications Of Transplanted Lung: 1 person, 9.09%
Depressed Level Of Consciousness: 1 person, 9.09%

What are the existing conditions these people have? *

Staphylococcal Infection (an infection with staphylococcus bacteria): 2 people, 18.18%
Lymphoma (cancer that begins in immune system cells): 2 people, 18.18%
Wound Infection: 1 person, 9.09%
Renal Disorder (kidney disease): 1 person, 9.09%
Post Procedural Infection: 1 person, 9.09%
Osteomyelitis (infection of bone): 1 person, 9.09%
Kidney Infection: 1 person, 9.09%
High Blood Cholesterol: 1 person, 9.09%
Device Related Infection: 1 person, 9.09%
Bacteraemia (presence of bacteria in the blood): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Cubicin and have Hearing loss?

- Check whether Hearing loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cubicin:

Cubicin (7,991 reports)

Hearing loss treatments and more:

Hearing loss (30,352 reports)

Browse all side effects of Cubicin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hearing loss:

Hearing loss (1,355 drugs)

Browse all the conditions that are associated with Hearing loss:

Hearing loss (2,378 conditions)

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Saliho?lu M, Turhan V, ?nem Y, Ulcay A, Uzun G, Ay H, "Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection", Scandinavian journal of infectious diseases, 2013 Mar .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Saliho?lu M, Turhan V, ?nem Y, Ulcay A, Uzun G, Ay H, "Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection", Scandinavian journal of infectious diseases, 2013 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on daptomycin (the active ingredients of Cubicin) and Cubicin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.